ARCA biopharma Inc (ABIO)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading ARCA biopharma Inc chart...

About the Company

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.

Employees

13

CEO

Michael Bristow

Exchange

NASDAQ

Website

www.arcabiopharma.com

$M

Total Revenue

13

Employees

$34M

Market Capitalization

-1.91

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABIO News

Arca Biopharma inks merger deal that brings Oruka Therapeutics public

14d ago, source: BizWest

After nearly two years of searching, drug developer Arca Biopharma Inc. (Nasdaq: ABIO) has found a merger partner.

ARCA biopharma, Inc. (ABIO)

14h ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details

on MSN ago, source:

ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in ...

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

14d ago, source:

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with ...

ARCA Biopharma, Oruka Therapeutics To Combine In All-stock Deal - Quick Facts

14d ago, source:

ARCA biopharma, Inc. (ABIO), and Oruka Therapeutics have entered into a definitive agreement to combine in an all-stock deal. The ...

ARCA biopharma Inc ABIO

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

14d ago, source: Stockhouse

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third ...

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

14d ago, source: Yahoo Finance

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a ...

ARCA Biopharma And Oruka Therapeutics Announce Merger Agreement

14d ago, source: Mena FN

(MENAFN- GlobeNewsWire - Nasdaq) Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin ...

ARCA biopharma Inc

29d ago, source: U.S. News & World Report

Some funds make more sense to hold in a Roth IRA due to higher income generation, greater turnover or the potential for stronger long-term growth.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...